Literature DB >> 36100838

RNA therapeutics: updates and future potential.

Caroline Zhang1, Biliang Zhang2,3.   

Abstract

Recent advancements in the production, modification, and cellular delivery of RNA molecules facilitated the expansion of RNA-based therapeutics. The increasing understanding of RNA biology initiated a corresponding growth in RNA therapeutics. In this review, the general concepts of five classes of RNA-based therapeutics, including RNA interference-based therapies, antisense oligonucleotides, small activating RNA therapies, circular RNA therapies, and messenger RNA-based therapeutics, will be discussed. Moreover, we also provide an overview of RNA-based therapeutics that have already received regulatory approval or are currently being evaluated in clinical trials, along with challenges faced by these technologies. RNA-based drugs demonstrated positive clinical trial results and have the ability to address previously "undruggable" targets, which delivers great promise as a disruptive therapeutic technology to fulfill its full clinical potentiality.
© 2022. Science China Press and Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  RNA; RNA therapeutics; RNAi; mRNA vaccine

Year:  2022        PMID: 36100838      PMCID: PMC9470505          DOI: 10.1007/s11427-022-2171-2

Source DB:  PubMed          Journal:  Sci China Life Sci        ISSN: 1674-7305            Impact factor:   10.372


  105 in total

Review 1.  Regulation of circRNA biogenesis.

Authors:  Ling-Ling Chen; Li Yang
Journal:  RNA Biol       Date:  2015       Impact factor: 4.652

Review 2.  mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases.

Authors:  Giulietta Maruggi; Cuiling Zhang; Junwei Li; Jeffrey B Ulmer; Dong Yu
Journal:  Mol Ther       Date:  2019-02-07       Impact factor: 11.454

3.  Noncoding RNA: from dark matter to bright star.

Authors:  Yuanchao Xue; Runsheng Chen; Lianghu Qu; Xiaofeng Cao
Journal:  Sci China Life Sci       Date:  2020-03-13       Impact factor: 6.038

Review 4.  Global Overview of the Epidemiology of Atherosclerotic Cardiovascular Disease.

Authors:  Simon Barquera; Andrea Pedroza-Tobías; Catalina Medina; Lucía Hernández-Barrera; Kirsten Bibbins-Domingo; Rafael Lozano; Andrew E Moran
Journal:  Arch Med Res       Date:  2015-06-29       Impact factor: 2.235

5.  Systemic delivery of factor IX messenger RNA for protein replacement therapy.

Authors:  Suvasini Ramaswamy; Nina Tonnu; Kiyoshi Tachikawa; Pattraranee Limphong; Jerel B Vega; Priya P Karmali; Pad Chivukula; Inder M Verma
Journal:  Proc Natl Acad Sci U S A       Date:  2017-02-15       Impact factor: 11.205

6.  Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol.

Authors:  Kausik K Ray; R Scott Wright; David Kallend; Wolfgang Koenig; Lawrence A Leiter; Frederick J Raal; Jenna A Bisch; Tara Richardson; Mark Jaros; Peter L J Wijngaard; John J P Kastelein
Journal:  N Engl J Med       Date:  2020-03-18       Impact factor: 91.245

7.  Programmable RNA editing by recruiting endogenous ADAR using engineered RNAs.

Authors:  Liang Qu; Zongyi Yi; Shiyou Zhu; Chunhui Wang; Zhongzheng Cao; Zhuo Zhou; Pengfei Yuan; Ying Yu; Feng Tian; Zhiheng Liu; Ying Bao; Yanxia Zhao; Wensheng Wei
Journal:  Nat Biotechnol       Date:  2019-07-15       Impact factor: 54.908

Review 8.  The Potential for microRNA Therapeutics and Clinical Research.

Authors:  Johora Hanna; Gazi S Hossain; Jannet Kocerha
Journal:  Front Genet       Date:  2019-05-16       Impact factor: 4.599

9.  A randomized study to evaluate safety and immunogenicity of the BNT162b2 COVID-19 vaccine in healthy Japanese adults.

Authors:  Miwa Haranaka; James Baber; Yoichiro Ogama; Masako Yamaji; Masakazu Aizawa; Osamu Kogawara; Ingrid Scully; Eleni Lagkadinou; Ӧzlem Türeci; Uğur Şahin; Philip R Dormitzer; William C Gruber; Stephen Lockhart
Journal:  Nat Commun       Date:  2021-12-14       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.